Inside Meso Scale Discovery (MSD)

A Newsletter Series from Aim Discovery Solutions — Issue 2

Welcome to Meso Scale Discovery (MSD) Technology newsletter #2 from Aim Discovery Solutions. This series is designed to help researchers across Australia and New Zealand get to know the technologies, applications, and practical advantages behind MSD. Aim Discovery Solutions connects researchers with high-quality life science and diagnostic technologies, supported by personalised service and local expertise.

Ten answers from one well: Why MULTI-ARRAY is not just a faster ELISA

ELISA makes you pick a lane, whereas MSD MULTI-ARRAY technology lets you read the whole panel from the sample you already have. MSD's argument is that the bottleneck in immunoassay work is no longer “can we detect this protein?” It is whether you can measure the right set of analytes, in a scarce or messy sample, without a dilution series and a week of plate work. The answer is a plate that combines a printed antibody array with electrochemiluminescence technology.

What is happening in the well?

A MULTI-ARRAY assay is still a sandwich immunoassay. Capture antibody, sample, detection antibody. The difference is where that sandwich sits, and how it is read.
Capture antibodies are printed as discrete spots on the bottom of the well — up to 10 spots in 96-well or 4 spots in 384-well MULTI-SPOT plates. Each spot is a separate assay. A detection antibody carries a SULFO-TAG label. When the instrument applies a voltage to the electrode in the plate, labels near that surface emit light at about 620 nm, and a camera reads each spot on its own. Spots are assigned based on the number of analytes being detected to ensure optimal performance: ten readouts from one incubation, not ten plates.



MULTI-SPOT plates, which offer arrays within the well for increased throughput and assay multiplexing, are available in 96- and 384-well formats, with up to 10 spots per well.

Two design choices do most of the analytical work. The stimulus is electricity and the signal is light, so the two are decoupled and background stays low. And only labels close to the electrode are excited, which is why unbound reagent contributes little and why the platform is less troubled by colour and matrix than a colorimetric ELISA. Each label is also cycled through multiple excitation rounds, which is how the signal is amplified without an enzyme step.

	ELISA	MSD
Sample	50–100 µL per analyte	10–25 µL for up to 10 analytes
Multiplex	No	Up to 10 per well
Panel design	Fixed	Reconfigurable with U-PLEX
Dynamic range	1–2 logs	3–4+ logs
Matrix effects	Common	Greatly reduced
Washes	Many	Typically 1–3
Read	Slow	Up to 960 results in 1–3 minutes
Instrument	Daily cleaning & calibration	No user maintenance

Read down that table and the experiment changes shape. Ten singleplex ELISAs can consume 500–1,000 µL before you have a panel. The same ten analytes on a MULTI-SPOT well are specified at 10–25 µL total. A 3–4 log range, against 1–2 logs for a typical ELISA, is why MSD says fewer samples fall below the detection limit, and why elevated and normal samples can often be run without a stack of dilutions. Fewer washes and a plate read in one to three minutes are the throughput half of the same argument. Transferring an existing ELISA onto the platform is described as often taking less than two days, with minimal optimization.
The sensitivity claim is deliberately modest: multiplexed spots are said to hold sensitivity comparable to a conventional single-analyte assay, with precision held across that wider range. This is not "ELISA, but fluorescent." It is a different detection physics, plus an array, plus a reader that does not need a daily clean.

In Summary
One well, up to ten analytes, a fraction of the sample, and a range wide enough that you stop designing the experiment around the assay.
If a cytokine, biomarker, or signalling panel is still a row of singleplex ELISAs, the question is no longer whether multiplexing exists. It is whether those extra spots are worth the sample currently being spent on the first analyte.

Ready to explore what MSD technology can do for your research?

Contact Aim Discovery Solutions to discuss MSD ECL assays, multiplex panels, assay development options, and application support for your next biomarker study.

Contact

E: mesoscale@aimdiscovery.com
W: https://aimdiscovery.com